At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 468 enrolled
Drug / intervention
ASP2151 +1 moredrug
Likely dose
ASP2151 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Study of ASP2151 in Herpes Simplex Patients - A Double-blind, Placebo-controlled Study -
In Brief
A Phase 3 clinical trial evaluating ASP2151 and ASP2151 placebo for Herpes Simplex. Completed, enrolled 468 participants across 3 sites.
Detailed Summary
To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Simplex
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedOct 2013
Primary CompletionApr 2015
Study CompletionApr 2015
TodayJul 2026
First PostedOct 10, 2013
Enrollment StartAug 1, 2013
Primary CompletionApr 1, 2015
Study CompletionApr 27, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.7 years ago
Interventions
ASP2151drug
200 mg once daily
ASP2151 placebodrug
once daily